Please ensure Javascript is enabled for purposes of website accessibility

Automakers Roll Out a SEMI

By Brian Gorman – Updated Nov 16, 2016 at 2:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GM, Ford, and DaimlerChrysler are collaborating to slow drug-cost increases.

Even among the most competitive rivals, sometimes it pays to cooperate. In this case, all participants stand to win from a new partnership among three automakers.

General Motors (NYSE:GM), Ford (NYSE:F), and DaimlerChrysler (NYSE:DCX) jointly announced on Wednesday that they are launching the Southeast Michigan e-Prescribing Initiative, or SEMI, to streamline the drug prescribing process. As part of the project, physicians will use computers or wireless devices to write and send prescriptions electronically to a pharmacy for filling.

SEMI's primary goal is to reduce prescribing errors and head off potentially harmful drug interactions. However, the group notes, e-prescribing has an added benefit. Pharmacy benefit manager Medco Health Solutions (NYSE:MHS), which is participating in the venture, has evidence that physicians who e-prescribe tend to increase their generic substitution rates by an average of more than 15% and their generic dispensing rates by more than 8%. With drug formularies on the same devices that physicians use to write prescriptions, doctors are more likely to see and choose generics.

Automakers, especially General Motors, have been particularly adamant about the need to curb health care costs. At the Detroit Regional Chamber's Mackinac Policy Conference last year, GM Chairman Richard Wagoner said he views rising health costs as a national crisis. His concerns are understandable: GM, the nation's largest private insurer, expects its health bill to jump 23% to $5.3 billion in 2005, according to The Detroit News. Prescription drug expenses alone are forecast to climb 15%, a growth rate that will have a major impact on bottom lines.

For now, SEMI is just a limited experiment. But, if successful, it will likely be rolled out across the country. The program is no magic bullet, but even a small improvement may be worth getting excited about.

See also:

Fool contributor Brian Gorman is a freelance writer in Chicago. He does not own shares of any companies mentioned in this article.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ford Motor Company Stock Quote
Ford Motor Company
F
$11.99 (-2.60%) $0.32
General Motors Company Stock Quote
General Motors Company
GM
$35.04 (-1.24%) $0.44
Medco Health Solutions, Inc. Stock Quote
Medco Health Solutions, Inc.
MHS.DL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.